This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hwang, J. H. Articles by Shong, M. Search for Related Content PubMed PubMed Citation Articles by Hwang, J. H. Articles by Shong, M.

Activation of Signal Transducer and Activator of Transcription 3 by Oncogenic RET/PTC (Rearranged in Transformation/Papillary Thyroid Carcinoma) Tyrosine Kinase: Roles in Specific Gene Regulation and Cellular Transformation

Laboratory of Endocrine Cell Biology (J.H.H., D.W.K., J.M.S., H.K., J.H.S., E.S.H., K.C.P., E.S.H., K.C.P., H.K.C., M.S.), National Research Laboratory Program, Department of Internal Medicine, Department of Pathology (J.M.K.), Chungnam National University School of Medicine, Daejeon 301-721, Korea; and Korea Research Institute of Bioscience and Biotechnology (T.-H.L., D.-Y. Y.), Yusong, Daejeon 305-600, Korea

Address all correspondence and requests for reprints to: Minho Shong, Laboratory of Endocrine Cell Biology, Department of Internal Medicine, Chungnam National University College of Medicine, 640 Daesadong Chungku, Daejeon 301-721, Korea. E-mail: minhos{at}cnu.ac.kr.

Thyroid papillary carcinomas are characterized by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) rearrangements that result in fusion of the tyrosine kinase domain of the RET receptor to the N-terminal sequences encoded by heterologous genes. This thyroid-specific rearrangement causes aberrant expression of RET/PTC and results in constitutive ligand-independent activation of RET kinase. However, it is unclear how RET/PTC activates the specific signaling pathways for cellular transformation. In this study, we show that RET/PTC associates with signal transducer and activator of transcription 3 (STAT3) and activates it by the specific phosphorylation of the tyrosine 705 residue. Activation of STAT3 requires the intrinsic kinase activity of RET/PTC; Janus tyrosine kinase and c-Src kinase are not involved in the RET/PTC-mediated activation of STAT3. RET/PTC-induced activation of STAT3 induces the STAT3-responsive genes, vascular endothelial growth factor, cyclin D1, and intercellular adhesion molecule 1. In addition, RET/PTC-mediated cellular transformation and proliferation of transformed cells require tyrosine 705 phosphorylation of STAT3 in NIH3T3 cells. We conclude that STAT3 activation by the RET/PTC tyrosine kinase is one of the critical signaling pathways for the regulation of specific genes, such as cyclin D1, vascular endothelial growth factor, and intercellular adhesion molecule 1, and for cellular transformation.

This article has been cited by other articles:

				D. W. Kim, H. K. Chung, K. C. Park, J. H. Hwang, Y. S. Jo, J. Chung, D. V. Kalvakolanu, N. Resta, and M. Shong Tumor Suppressor LKB1 Inhibits Activation of Signal Transducer and Activator of Transcription 3 (STAT3) by Thyroid Oncogenic Tyrosine Kinase Rearranged in Transformation (RET)/Papillary Thyroid Carcinoma (PTC) Mol. Endocrinol., December 1, 2007; 21(12): 3039 - 3049. [Abstract] [Full Text] [PDF]

				I. Plaza-Menacho, T. van der Sluis, H. Hollema, O. Gimm, C. H. C. M. Buys, A. I. Magee, C. M. Isacke, R. M. W. Hofstra, and B. J. L. Eggen Ras/ERK1/2-mediated STAT3 Ser727 Phosphorylation by Familial Medullary Thyroid Carcinoma-associated RET Mutants Induces Full Activation of STAT3 and Is Required for c-fos Promoter Activation, Cell Mitogenicity, and Transformation J. Biol. Chem., March 2, 2007; 282(9): 6415 - 6424. [Abstract] [Full Text] [PDF]

				D. W. Kim, Y. S. Jo, H. S. Jung, H. K. Chung, J. H. Song, K. C. Park, S. H. Park, J. H. Hwang, S. Y. Rha, G. R. Kweon, et al. An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4070 - 4076. [Abstract] [Full Text] [PDF]

				Y. S. Jo, S. Li, J. H. Song, K. H. Kwon, J. C. Lee, S. Y. Rha, H. J. Lee, J. Y. Sul, G. R. Kweon, H.-k. Ro, et al. Influence of the BRAF V600E Mutation on Expression of Vascular Endothelial Growth Factor in Papillary Thyroid Cancer J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3667 - 3670. [Abstract] [Full Text] [PDF]

				C. Mesa Jr., M. Mirza, N. Mitsutake, M. Sartor, M. Medvedovic, C. Tomlinson, J. A Knauf, G. F. Weber, and J. A. Fagin Conditional Activation of RET/PTC3 and BRAFV600E in Thyroid Cells Is Associated with Gene Expression Profiles that Predict a Preferential Role of BRAF in Extracellular Matrix Remodeling. Cancer Res., July 1, 2006; 66(13): 6521 - 6529. [Abstract] [Full Text] [PDF]

				H. S. Jung, D. W. Kim, Y. S. Jo, H. K. Chung, J. H. Song, J. S. Park, K. C. Park, S. H. Park, J. H. Hwang, K.-W. Jo, et al. Regulation of Protein Kinase B Tyrosine Phosphorylation by Thyroid-Specific Oncogenic RET/PTC Kinases Mol. Endocrinol., November 1, 2005; 19(11): 2748 - 2759. [Abstract] [Full Text] [PDF]

				E Puxeddu, J A Knauf, M A Sartor, N Mitsutake, E P Smith, M Medvedovic, C R Tomlinson, S Moretti, and J A Fagin RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response Endocr. Relat. Cancer, June 1, 2005; 12(2): 319 - 334. [Abstract] [Full Text] [PDF]

				E. S. Hwang, D. W. Kim, J. H. Hwang, H. S. Jung, J. M. Suh, Y. J. Park, H. K. Chung, J. H. Song, K. C. Park, S. H. Park, et al. Regulation of Signal Transducer and Activator of Transcription 1 (STAT1) and STAT1-Dependent Genes by RET/PTC (Rearranged in Transformation/Papillary Thyroid Carcinoma) Oncogenic Tyrosine Kinases Mol. Endocrinol., November 1, 2004; 18(11): 2672 - 2684. [Abstract] [Full Text] [PDF]